• Chosa Oncology on Nov. 9, 2026, highlighted a Nov. 4 agreement with a CLIA-certified laboratory to develop Platin-DRP for US commercialization.
• First commercial revenue is expected in summer 2027, subject to successful analytical validation of the laboratory-developed test.
• Estimated US market potential exceeds 250,000 tests annually, with first-year sales projected at 300-500 tests.
• Previously presented SPLENDOUR trial results showed longer survival among advanced lung cancer patients predicted by Platin-DRP to benefit from platinum chemotherapy.
• Expert discussions at ESMO 2026 highlighted demand for personalized platinum treatment, with several participants expressing interest in potential collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.